Evaluation of Antiphospholipid Antibodies and Activated Partial Thromboplastin Time in Women with Adverse Outcome of Pregnancy
Authors
Abstract:
Adverse outcome of pregnancy is a potentially dangerous complication of conception and affects 15-20% of pregnancies. According to recent studies increased level of blood antiphospholipids antibodies, if accompanied by predisposing factors, can be an adverse event in human pregnancy. The aim of the present study was to compare the maternal serum levels of anticardiolipin and antiphosphatidyl serine, and partial thromboplastin time between patients with adverse outcome of pregnancy and matched subjects with normal pregnancy. Serum levels of anticardiolipin and antiphosphatidyl serine and activated partial thromboplastin time were measured in 150 women with adverse pregnancy outcome and 150 matched women with normal pregnancy after a gestational age of 10 weeks. Data on maternal age, age of pregnancy, serum levels of anticardiolipin and antiphosphatidyl serine, and activated partial thromboplastin time were collected and compared by Student’s t or χ 2 tests. The age of mothers in the two groups were 25.86±5.90 and 27.09±5.63 years (P=0.67), and the age of pregnancies were 29.34±5.12 and 28.17±7.03 (P=0.1) weeks in the control and patient groups, respectively. Positive levels of serum anticardiolipin and antiphosphatidyl serine antibodies, and activated partial thromboplastin time for the control and patient groups were 14.3% versus 85.7% (P=0.002), 15.2 % versus 84.8 % (P=0.003), and 23.1 % versus 76.9% (P=0.001), respectively. The findings suggest that positive levels of serum antiphospholipids are associated with adverse outcome of pregnancy in the study population.
similar resources
evaluation of antiphospholipid antibodies and activated partial thromboplastin time in women with adverse outcome of pregnancy
adverse outcome of pregnancy is a potentially dangerous complication of conception and affects 15-20% of pregnancies. according to recent studies increased level of blood antiphospholipids antibodies, if accompanied by predisposing factors, can be an adverse event in human pregnancy. the aim of the present study was to compare the maternal serum levels of anticardiolipin and antiphosphatidyl se...
full textLaboratory Methodologic Approach in Prolonged Activated Partial Thromboplastin Time Test
The pathological activated partial thromboplastin time test is a data that we can find in all clinical laboratories routinely. The hemato-coagulative clinical case here reported aims to point out how the laboratory can provide a correct diagnosis by methodological rational setting and, consequently, carry out an appropriate therapy, or reassure the patient that the pathological data will not ca...
full textComparison of Antiphospholipid Antibodies between Preeclamptsia and Normal Pregnant Women
Antiphospholipid antibodies (APLA) may be detected in normal pregnancies and also may cause thrombosis, recurrent fetal loss, placental infarction and preeclampsia. In the present study the possible differences in APLA titer between healthy pregnant women and preeclampsia cases without history of thrombosis was examined. The APLA titer in 50 healthy pregnant women with 50 preeclampsia cases wit...
full textAdverse Pregnancy Outcome in Antiphospholipid Antibodies Syndrome: Pathogenic Mechanisms and Clinical Management
full text
Leader How to treat women with antiphospholipid antibodies in pregnancy?
The persistent presence in plasma of medium to high levels of IgG and/or IgM class anticardiolipin antibodies (aCL) and/or the lupus anticoagulant (LAC) is associated with both “recurrent pregnancy loss” and venous and arterial thrombosis. This clinicoserological entity, first described in the early eighties in patients with systemic lupus erythematosus was termed the antiphospholipid syndrome ...
full textMy Resources
Journal title
volume 35 issue 4
pages 315- 318
publication date 2010-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023